Litigation Details for Intercept Pharmaceuticals, Inc. v. Apotex Inc. (D. Del. 2020)
✉ Email this page to a colleague
Intercept Pharmaceuticals, Inc. v. Apotex Inc. (D. Del. 2020)
| Docket | ⤷ Sign Up | Date Filed | 2020-08-21 |
| Court | District Court, D. Delaware | Date Terminated | 2023-02-24 |
| Cause | 35:271 Patent Infringement | Assigned To | Maryellen Noreika |
| Jury Demand | None | Referred To | |
| Parties | MSN LABORATORIES PRIVATE LIMITED | ||
| Patents | 10,047,117; 10,052,337; 10,174,073; 7,138,390; 9,238,673 | ||
| Attorneys | Jovial Wong | ||
| Firms | UNDELIVERABLE EMAIL 11/9/2021, Schiff Hardin LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Intercept Pharmaceuticals, Inc. v. Apotex Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Intercept Pharmaceuticals, Inc. v. Apotex Inc. (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2022-02-03 | 115 | Joint Claim Construction Brief | “’673 Patent” refers to U.S. Patent No. 9,238,673. “’117 Patent” refers to U.S. Patent No. 10,047,117…“’073 Patent” refers to U.S. Patent No. 10,174,073. “’337 Patent” refers to U.S. Patent No. 10,052,337…“’349 Patent” refers to U.S. Patent No. 10,751,349. “’549 Patent” refers to U.S. Patent No. 10,758,549…compositions—expire. Patents from three patent families are asserted in this case. The ’673 Patent Family, which…and ’073 Patents, and the ’337 Patent Family, which includes the ’337, ’349, and ’549 Patents. The ’673 | External link to document |
| 2022-02-28 | 137 | Claim Construction Chart | regarding U.S. Patent No. 9,238,673 (“the ’673 Patent”), U.S. Patent No. 10,047,117 (“the ’117 Patent”), U.S.…U.S. Patent No. 10,174,073 (“the ’073 Patent”), U.S. Patent No. 10,052,337 (“the ’337 Patent”), U.S. Patent… ’349 Patent”), and U.S. Patent No. 10,758,549 (“the ’549 Patent”) (collectively, the “Patents-in-Suit…particles 1 U.S. Patent No. RE48,286 (“the RE286 Patent”) is also an asserted patent in this case. It … ’673 Patent (claims 1–23) ’073 Patent (claims | External link to document |
| 2022-03-23 | 142 | Order - -Memorandum and Order | terms of U.S. Patent Nos. 9,238,673 (“the ’673 Patent”), 10,047,117 (“the ’117 Patent”), 10,174,073 …of the ’673 Patent, the ’117 Patent, the ’337 Patent, the ’349 Patent, and the ’549 Patent are construed…10,174,073 (“the ’073 Patent”), 10,052,337 (“the ’337 Patent”), 10,751,349 (“the ’349 Patent”), and 10,758,549… matter” (’337 Patent, claims 1–8; ’349 Patent, claims 1, 19; ’549 Patent, …meaning (’337 patent, claim 11; ’349 patent, claim 4; ’549 patent, claims 12, 23 | External link to document |
| 2020-11-12 | 15 | Complaint - Amended | expiration of U.S. Patent Nos. 9,238,673 (filed June 17, 2013) (“the ’673 patent”); 10,047,117 (filed Nov. …Notification of Certification for U.S. Patent Nos. 9,238,673; 10,047,117; 10,052,337; and 10,174,073 (NDA … ’073 patent”); 10,758,549 (filed Feb. 11, 2020) (“the ’549 patent”) (collectively the “patents-in-suit… 1. This action for patent infringement, brought pursuant to the patent laws of the United States…20, 2015) (“the ’117 patent”); 10,052,337 (filed Apr. 26, 2016) (“the ’337 patent”); 10,174,073 (filed | External link to document |
| 2020-11-12 | 16 | Patent/Trademark Report to Commissioner of Patents | Commissioner of Patents and Trademarks for Patent/Trademark Number(s): 9,238,673 B2; 10,047,117 B2; 10,052,… 21 August 2020 1:20-cv-01105 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
